8-K filing — BIO-TECHNE Corp (TECH)
Filed: 2026-09-14 AccNo: 0001140361-26-036499 Size: 204 KB Item 8.01: Other Events
Stocks · News reference
Wells Fargo Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73
Wells Fargo analyst Brandon Couillard downgrades Bio-Techne (NASDAQ:TECH) from Overweight to Equal-Weight and raises the price target from $62 to $73.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?
Bio-Techne (TECH) reported Q4 adjusted EPS of 52 cents, meeting consensus estimates but declining 1.9% year-over-year. Full-year adjusted EPS of $1.93 increased 0.5% and surpassed consensus by 1%. Q4 revenues of $321.2 million exceeded estimates by 1.26%, though organic growth was modest at 3%. The company improved its balance sheet with cash increasing to $264.7 million and debt declining to $200 million. However, analysts have issued no estimate revisions in the past two months, and the stock carries a Zacks Rank #3 (Hold) with weak growth and momentum scores.
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger – AUUD, TECH, CZR and CBAN
Monteverde & Associates PC is investigating four major merger and acquisition deals to determine if they are fair to shareholders: Auddia's merger with McCarthy Finney (1:1 stock exchange), Bio-Techne's sale to Merck KGaA ($73/share), Caesars Entertainment's sale to Fertitta Gaming ($31/share plus ticking consideration), and Colony Bankcorp's merger with First Reliance Bancshares ($19.75 cash or 0.94 stock exchange).
Global Multiplex Assays Market 2026 Edition - Consumables Dominate Multiplex Assays with 68% Market Share
The global multiplex assays market is projected to grow from US$6.8 billion in 2025 to US$12.4 billion by 2030, at a 12.8% CAGR. North America leads with 34% market share, while Asia Pacific is the fastest-growing region at 15.5% CAGR. Consumables dominate with 68% market share, and protein multiplex assays hold 42%. Growth is driven by precision medicine, companion diagnostics, and laboratory automation.